Phillip Grob
Geriatric Psychiatry · Santa Rosa, CANPI 1588725253
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 33.7% of the total. Reporting peaked in 2023 at $1,152 and has fallen 64.9% since, to $404 in 2025.
Across 151 payments — averaging $22.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- AbbVie$756
- Teva Pharmaceuticals USA, Inc.$348
- Johnson & Johnson$242
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$199
- Alkermes, Inc.$157
- plus $577 from 9 others
What the payments were for
- Food & beverage$3,39099%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 41 | $1,159 |
| AbbVie(2 entities) | 42 | $756 |
| Teva Pharmaceuticals USA, Inc. | 13 | $348 |
| Johnson & Johnson | 10 | $242 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $199 |
| Alkermes, Inc. | 8 | $157 |
| Indivior Inc. | 7 | $147 |
| Otsuka America Pharmaceutical, Inc. | 7 | $141 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Lundbeck LLC | 3 | $61 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $61 |
| E.r. Squibb & Sons, L.L.C. | 2 | $53 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $13 |
| Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$105
How this compares
$3,437 in reported general payments places this provider in the 85th percentile of 46 geriatric psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 39 | $139,839 |
| IngrezzaValbenazine Tosylate | 19 | $114,661 |
| VraylarCariprazine Hcl | 44 | $45,787 |
| LybalviOlanzapine/Samidorphan Malate | 18 | $28,495 |
| CaplytaLumateperone Tosylate | 15 | $23,821 |
| Aripiprazole | 107 | $17,581 |
| Clozapine | 177 | $16,409 |
| Asenapine Maleate | 35 | $8,860 |
| Olanzapine OdtOlanzapine | 91 | $8,849 |
| FanaptIloperidone | 13 | $7,965 |
| Quetiapine Fumarate | 264 | $6,402 |
| Clozapine OdtClozapine | 30 | $4,626 |
| Chlorpromazine Hcl | 32 | $4,108 |
| Divalproex Sodium | 98 | $4,078 |
| Olanzapine | 104 | $3,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $242 | $139,83939 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,159 | $114,66119 claims |
| AbbVieVraylar | $756 | $45,78744 claims |
| Alkermes, Inc.Lybalvi | $157 | $28,49518 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $199 | $23,82115 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $71 | $7,96513 claims |
| Teva Pharmaceuticals USA, Inc.Loxapine | $348 | $92518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 46 geriatric psychiatry providers in California.
Other geriatric psychiatry in Santa Rosa
- David SultzerLos Angeles$203K
- Kristine YaffeSan Francisco$40K
- James NelsonSan Francisco$31K
- Samir SabbagMonterey$15K
- Harsukh SavaliaCerritos$9K
- Barbara HuynhLos Angeles$4K
- Jasdeep AulakhPatton$3K
- Kyle BechazLos Angeles$1K
- Beverly ChangRoseville$842
- Izzet YazganCapitola$785
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.